Ahmedabad-based Cadila Pharmaceuticals has announced the launch of the world's first aqueous formulation of cholecalciferol, setting a new benchmark in the treatment of Vitamin D deficiency.

This ground-breaking innovation demonstrates superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to traditional oil-based cholecalciferol preparations available in the market.

Vitamin D deficiency is a major health concern globally, contributing significantly to the outcomes of various diseases. Cadila Pharmaceuticals' innovative aqueous cholecalciferol injection offers a unique solution with rapid correction of Vitamin D deficiency in short span of time.

The breakthrough not only enhances the efficacy of treatment but also ensures a painless and easy administration process, marking a significant advancement in patient care.

Patients can benefit from a swift correction of Vitamin D deficiency in short span of time, addressing a critical need for expedited treatment outcomes in many major illnesses.

Significance of Vitamin D extends well beyond bone health, influencing outcomes in various conditions such as Cardiovascular Disease, Diabetes Mellitus, and weakened immune systems. Vitamin D acts as an anti-hypertrophic agent, a stimulator of vascular smooth muscle cell proliferation, anti- fibrotic, antioxidant, anti-inflammatory, and an inhibitor of the Renin-Angiotensin-Aldosterone System (RAAS).

By introducing the world's first aqueous cholecalciferol injection, through totally indigenous research, the company envisions a paradigm shift in addressing Vitamin D deficiency globally.